A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Trial details
- Registry ID
- NCT05980806
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as KPT-330; Xpovio®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806 | KPTI | Phase 2 | Recruiting | 2027-06Estimated |
| Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentNCT04256707 | KPTI | Phase 1, Phase 2 | Completed | 2024-07-31Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |